Yokoyama Masaru, Urakawa Masami, Murakami Tetsuo, Amano Kunihiko, Ohsawa Tomonori, Okada Norimichi, Kumamoto Kensuke, Ishibashi Keiichiro, Ishida Hideyuki
Dept. of Surgery, Higashimatsuyama Medical Association Hospital.
Gan To Kagaku Ryoho. 2011 Nov;38(12):2241-3.
The safety and usefulness of FOLFOX therapy for elderly patients with metastatic colorectal cancer have not been clarified yet. We report an extremely aged patient case of metastatic colorectal cancer that was treated successfully with modified FOLFOX6 (mFOLFOX6) plus bevacizumab therapy. An 85-year-old man was diagnosed as having a low rectal cancer with paraaortic and left inguinal lymph node involvement. He was given mFOLFOX6 therapy after sigmoid colostomy. Bevacizumab was added to mFOLFOX6 after the second course. Although he experienced grade 2 neurtropenia and grade 1 neurotoxicity, the maximal diameter of the metastatic lymph nodes was decreased to a normal diameter after 9 courses. The primary tumor also disappeared and the biopsy revealed no cancer cells. He remains free of recurrence for 12 months after the end of chemotherapy.
FOLFOX疗法对老年转移性结直肠癌患者的安全性和有效性尚未明确。我们报告了一例极高龄转移性结直肠癌患者，通过改良FOLFOX6（mFOLFOX6）联合贝伐单抗治疗获得成功。一名85岁男性被诊断为低位直肠癌伴腹主动脉旁和左腹股沟淋巴结受累。乙状结肠造口术后给予mFOLFOX6治疗。第二个疗程后在mFOLFOX6基础上加用贝伐单抗。尽管他出现了2级中性粒细胞减少和1级神经毒性，但9个疗程后转移性淋巴结的最大直径缩小至正常大小。原发肿瘤也消失了，活检未发现癌细胞。化疗结束后12个月他仍无复发。
Zotero 插件